United Therapeutics Reports 7% Revenue Growth to $799.5 Million in Q3 2025

United Therapeutics Corporation reported its financial results for the third quarter and nine months ended September 30, 2025, revealing a total revenue of $799.5 million for the quarter, a 7% increase from $748.9 million in the same period last year. For the nine-month period, revenues rose 12% to $2.39 billion compared to $2.14 billion in 2024. The company achieved a net income of $338.7 million for the third quarter, up from $309.1 million a year earlier, and a year-to-date net income of $970.4 million, compared to $893.8 million in the prior year.

The increase in revenue was primarily driven by a 10% rise in total sales of the Tyvaso product line, which includes Tyvaso DPI and Nebulized Tyvaso, attributed to higher patient utilization and increased quantities sold. Tyvaso DPI alone saw a 22% increase in sales for the quarter, while Nebulized Tyvaso experienced a decline in sales due to higher gross-to-net revenue deductions. Orenitram also reported a 16% increase in sales, reflecting a growing patient base following the implementation of the Medicare Part D benefit redesign under the Inflation Reduction Act.

In terms of operational developments, United Therapeutics has been actively expanding its product offerings and capabilities. The company launched a new patient-filled version of the Remunity Pump in September 2025, aimed at enhancing patient experience. Additionally, the company is advancing its research and development efforts, with ongoing clinical trials for Nebulized Tyvaso in treating idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The TETON 2 study recently met its primary efficacy endpoint, and results from the TETON 1 study are expected in the first half of 2026.

Financially, the company reported a decrease in cash and cash equivalents to $1.34 billion as of September 30, 2025, down from $1.70 billion at the end of 2024. Marketable investments also saw a decline, while total assets remained relatively stable at $7.35 billion. The company’s total liabilities decreased to $760.9 million, down from $920 million at the end of the previous fiscal year. United Therapeutics has also engaged in significant share repurchase activities, with a $1 billion program approved in July 2025, which includes accelerated share repurchase agreements with Citibank.

Looking ahead, United Therapeutics anticipates continued revenue growth driven by the expansion of its product lines and the increasing number of patients treated with its therapies. The company is focused on navigating the competitive landscape, particularly with the recent launch of Liquidia's Yutrepia, which competes directly with its treprostinil-based products. The company remains committed to its long-term goals, including the development of manufactured organs and organ alternatives, which it views as complementary to its existing therapeutic offerings.